Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy

Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent chemoradiotherapy. Outcomes remain poor, with 5-year survival of only 20%. Despite the long-held belief that higher radiation doses lead to improved overall survival (OS), the landmark randomized trial (RTOG 0617) showed the opposite. The investigators hypothesize that the inferior survival observed may be due to unexpected heart toxicity as secondary analysis revealed that the heart dose was a strong predictor of inferior OS. Up to now, change in heart function is typically detected histologically, requiring autopsy tissue. Therefore, a non-invasive marker of early heart damage is required. Hybrid PET-MRI has become available in Canada only recently. The ability to simultaneously perform metabolic imaging with functional and tissue imaging allows for novel assessment of heart toxicity. The primary objective is to examine the utility of hybrid PET-MRI and DCE-CT to assess acute changes in heart function and to measure inflammation before, and six weeks after NSCLC radiotherapy. A pilot of 20 patients with Stage I-III NSCLC will be enrolled. The findings of this study will aid in the design of new studies to reassess dose escalation for locally advanced NSCLC while limiting the risk of heart toxicity. FDG PET will be used to simultaneously assess both cardiac inflammation and tumour response. Quantitative DCE-CT will also be used to measure ventilation and perfusion changes in the normal lung and tumour after radiotherapy, providing image data that can comprehensively assess both tumour response and potential toxicity in both the heart and lungs. Such information is crucial in understanding the disease and its response to treatment. This data will also aid in the design of radiation techniques that spare the heart in other patients with any thoracic malignancies, including breast cancer, lymphoma, and esophageal cancer.

Sex

All

Inclusion Criteria:

* Age 18 or older
* Ability to provide informed consent
* Histologically confirmed carcinoma of the lung
* Stage I-III NSCLC
* Stage I-II patients to receive 54 Gy in 3 fractions, 55 Gy in 5 fractions, or 60 Gy in 8 fractions (treated every other day)
* Stage III patient to receive concurrent chemoradiation ( 60 Gy in 30 daily fractions)
* No prior RT to the thorax
* ECOG performance status 0-1 within one month of accrual
* Expected lifespan at least 1 year
* Negative pregnancy test within one month of accrual if woman is premenopausal
* Patient presented at multidisciplinary tumor board or quality-assurance rounds
* Satisfactory pulmonary function tests as determined by the treating radiation oncologist (ie. FEV1 \>= 0.8 for Stage III NSCLC and no threshold for Stage I/II).

Exclusion Criteria:

* Patients receiving Prescription RT dose to anything other than LRCP standards for Stage I-III NSCLC.
* Prior history of atrial fibrillation
* Previous coronary bypass surgery
* Patients with severe reversible airways obstruction
* Patients with acute coronary syndrome (STEMI/non-STEMI and unstable angina)
* AV block without pacemaker
* Patients who are renal insufficient (eGFR \<40)
* Patients with asthma
* Allergy to iodinated contrast for scans (study subject will be eligible for non-contrast scans)
* Use of metformin-containing products less than 24 hours prior to CT contrast administration
* Other contraindications to iodinated contrast media as determined by the research team.
* Allergy to gadolinium for scans using contrast; will be eligible for non-contrast scans.
* Other contraindications to gadolinium contrast media as determined by the research team.